226396-31-2

Usage

Uses

Used in Organic Synthesis:
(4-METHYLAMINOSULPHONYL)BENZENE BORONIC ACID is used as a reagent for its capacity to engage in stable covalent bonding, facilitating the creation of new chemical entities in organic synthesis processes.
Used in Medicinal Chemistry:
In the realm of medicinal chemistry, (4-METHYLAMINOSULPHONYL)BENZENE BORONIC ACID is utilized as a versatile building block. Its presence allows for the development of pharmaceuticals with diverse applications, capitalizing on its ability to form stable bonds with biologically relevant molecules.
Used in Pharmaceutical Development:
(4-METHYLAMINOSULPHONYL)BENZENE BORONIC ACID is used as a key component in the preparation of pharmaceuticals, contributing to the advancement of new drugs and therapeutic agents.
Used in Agrochemical Production:
(4-METHYLAMINOSULPHONYL)BENZENE BORONIC ACID also finds application in agrochemicals, where it is used as a building block for the synthesis of various agrochemical products, potentially enhancing crop protection and yield.
Used in Material Science:
(4-METHYLAMINOSULPHONYL)BENZENE BORONIC ACID is employed in material science for the development of new materials, leveraging its bonding capabilities to create innovative material compositions with unique properties.

InChI:InChI=1/C7H10BNO4S/c1-9-14(12,13)7-4-2-6(3-5-7)8(10)11/h2-5,9-11H,1H3

Upstream product

• 703-12-8 4-bromo-N-methylbenzenesulphonamide 
• 5419-55-6 Triisopropyl borate 
• 98-58-8 4-bromobenzenesulfonyl chloride 

Downstream Products

• 68502-14-7 C₁₂H₁₁NO₄S 
• 936727-91-2 tert-butyl 6-(4-(N-methylsulfamoyl)phenyl)pyridin-2-ylcarbamate 

Relevant academic research and scientific papers

Design and synthesis of 1H-pyrazolo[3,4-b]pyridines targeting mitogen-activated protein kinase kinase 4 (MKK4) - A promising target for liver regeneration

Currently, the therapeutic options for treatment of liver failure are very limited. As mitogen-activated protein kinase kinase 4 (MKK4) has recently been identified by in vivo RNAi experiments to be a major regulator in hepatocyte regeneration, we pursued the development of a small molecule targeting this protein kinase. Starting from the approved BRAFV600E inhibitor vemurafenib (8), that showed a high off-target affinity to MKK4 in an initial screening, we followed a scaffold-hopping approach, changing the core heterocycle from 1H-pyrrolo[2,3-b]pyridine to 1H-pyrazolo[2,3-b]pyridine (10). Affinity to MKK4 could be conserved while the selectivity against off-target protein kinases was slightly improved. Further modifications led to 58 and 59 showing high affinity to MKK4 in the low nanomolar range and excellent selectivity profile from mandatory multiparameter-optimization for the essential anti-targets (MKK7, JNK1) and off-targets (BRAF, MAP4K5, ZAK) in the MKK4 pathway. Herein we report the first selective MKK4 inhibitors in this class.

PROTEIN KINASE MKK4 INHIBITORS FOR PROMOTING LIVER REGENERATION OR REDUCING OR PREVENTING HEPATOCYTE DEATH

The invention relates to pyrazolo-pyridine compounds which inhibit mitogen-activated protein kinase kinase 4 (MKK4) and in particular, selectively inhibit MKK4 over protein kinases JNK1 and MKK7. The compounds are useful for promoting liver regeneration or reducing or preventing hepatocyte death. They are further useful for treating osteoarthritis or rheumatoid arthritis, or CNS-related diseases.

HETEROCYCLIC MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS

Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette ("ABC") transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator ("CFTR"). T

Discovery of a potent CDK2 inhibitor with a novel binding mode, using virtual screening and initial, structure-guided lead scoping

Virtual screening against a pCDK2/cyclin A crystal structure led to the identification of a potent and novel CDK2 inhibitor, which exhibited an unusual mode of interaction with the kinase binding motif. With the aid of X-ray crystallography and modelling,